Awarded contract

NHS Framework Agreement for Branded Medicines - North, Midlands, East, and London Regions

Awarded
£201.7m
Published 23 Jun 2026

NHS is establishing a branded medicines framework agreement across English regions, with two separate lots for different geographical areas and contract durations starting September 2026.

United Kingdom· EnglandPublished 23 Jun 2026· 1 months agoFind a Tender

Decision brief

4 fields
  • Contract value
    £201,659,945
    Pounds sterling
  • Closing date
    Rolling
    No closing date published
  • Sector
    Browse related listings
  • Location
    United Kingdom
    England

Suppliers

25 suppliers

Lifecycle

Awarded

Contract awarded. Originally published 1 months ago.

23 June 2026
Awarded — no open tender advertised

Brief

This is an NHS Framework Agreement for the supply of branded medicines across multiple regions in England. The framework is divided into two lots: Lot 1 covers the North of England and Midlands & East regions, running from 1 September 2026 to 31 August 2028 with an optional extension of up to 24 months at the NHS's discretion. Lot 2 covers Natalizumab supply for London and South of England, running from 1 September 2026 to 31 August 2027 with an optional extension of up to 12 months. Suppliers should be prepared to provide branded medicines to support NHS services across these designated regions during the specified contract periods.

Track record

6 awards · 6 winners
Open panel

Mostly framework call-offs rather than head-to-head competition.

In healthcare medical, NHS ENGLAND has awarded 6 contracts to 6 suppliers.

Who wins here
  1. Amgen Ltd1× · 17%
  2. IMMUNOIVD AB1× · 17%
  3. ImmunoIVD1× · 17%

Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.

More from NHS ENGLAND

4 listingsView all →

Open in Healthcare & Medical

4 open listingsView all →